Tumor lysate-loaded biodegradable microparticles as cancer vaccines

Expert Review of Vaccines

Volumn 13, Issue 1, 2014, Pages 9-15

  Joshi, Vijaya B ^a   Geary, Sean M ^a   Gross, Brett P ^b   Wongrakpanich, Amaraporn ^a   Norian, Lyse A ^b   Salem, Aliasger K ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

biodegradable polymers; cancer; microparticles; tumor lysate; vaccine

Indexed keywords

ADJUVANT; CANCER VACCINE; PHOSPHORYL LIPID A; POLYGLACTIN; POLYMER; TUMOR ANTIGEN;

ARTICLE; BIODEGRADABILITY; DENDRITIC CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION;

ABSORBABLE IMPLANTS; CANCER VACCINES; CELL EXTRACTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICROSPHERES; NEOPLASMS; VACCINATION;

EID: 84893153864     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.851606     Document Type: Article

References (67)

1. Van Der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
2. Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006).
3. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
4. Mcneel DG, Dunphy EJ, Davies JG et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27(25), 4047-4054 (2009).
5. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009).
6. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006).
7. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J. Cell. Physiol. 228(7), 1404-1412 (2012).
8. Norian LA, Rodriguez PC, O'Mara LA et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 69(7), 3086-3094 (2009).
9. Le DT, Jaffee EM. Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J. Natl Compr. Cancer Netw. 11(7), 766-772 (2013).
10. Neumann E, Engelsberg A, Decker J et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 58(18), 4090-4095 (1998).
11. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin. Immunol. 20(5), 286-295 (2008).
12. De Gruijl TD, Van Den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57(10), 1569-1577 (2008).
13. Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid. 7, 93-103 (2012).
14. Sanchez-Perez L, Kottke T, Diaz RM et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65(5), 2009-2017 (2005).
15. Riker A, Cormier J, Panelli M et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126(2), 112-120 (1999).
16. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64(14), 4973-4979 (2004).
17. Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68(14), 5955-5964 (2008).
18. Prins RM, Wang X, Soto H et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J. Immunother. 36(2), 152-157 (2013).
19. Schaefer C, Butterfield LH, Lee S et al. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int. J. Cancer 131(4), 874-884 (2012).
20. Haanen JB, Baars A, Gomez R et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55(4), 451-458 (2006).
21. Weide B, Zelba H, Derhovanessian E et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J. Clin. Oncol. 30(15), 1835-1841 (2012).
22. Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG and Montanide ISA -51: association with survival. Int. J. Cancer 126(4), 909-918 (2010).
23. Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119-2127 (2011).
24. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48(20), 5883-5893 (1988).
25. Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine((R)). Semin. Cancer Biol. 13(6), 409-415 (2003).
26. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82(5), 488-496 (2004).
27. Schnurr M, Galambos P, Scholz C et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 61(17), 6445-6450 (2001).
28. Gitlitz BJ, Figlin RA, Pantuck AJ, Belldegrun AS. Dendritic cell-based immunotherapy of renal cell carcinoma. Curr. Urol. Rep. 2(1), 46-52 (2001).
29. Parajuli P, Mathupala S, Sloan AE. Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells. Neurosurgery 55(5), 1194-1204 (2004).
30. Win SJ, Mcmillan DG, Errington-Mais F et al. Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles. Br. J. Cancer 106(1), 92-98 (2012).
31. Prasad S, Cody V, Saucier-Sawyer JK et al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 7(1), 1-10 (2011).
32. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153(11), 4925-4933 (1994).
33. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-Mcdonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr. Opin. Microbiol. 13(1), 106-112 (2010).
34. Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 28(2), 215-236 (2011).
35. Wagner H. The immunogenicity of CpG-antigen conjugates. Adv. Drug Deliv. Rev. 61(3), 243-247 (2009).
36. Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK. A new horizon in modifications of chitosan: syntheses and applications. Crit. Rev. Ther. Drug Carrier Syst. 30(2), 91-181 (2013).
37. Salem AK, Hung CF, Kim TW, Wu TC, Searson PC, Leong KW. Multi-component nanorods for vaccination applications. Nanotechnology 16(4), 484-487 (2005).
38. Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40(1), 1-9 (2006).
39. Hanlon DJ, Aldo PB, Devine L et al. Enhanced stimulation of anti-ovarian cancer CD8+ T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Am. J. Reprod. Immunol. 65(6), 597-609 (2011).
40. Yoshikawa T, Okada N, Tsujino M et al. Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol. Pharm. Bull. 29(1), 100-104 (2006).
41. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3(12), 984-993 (2003).
42. Hildner K, Edelson BT, Purtha WE et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322(5904), 1097-1100 (2008).
43. Van Den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J. Immunol. 171(11), 5842-5852 (2003).
44. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin. Immunol. 8(5), 271-280 (1996).
45. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111(7), 927-930 (2002).
46. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J. 16(4), 382-391 (2010).
47. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(4 Suppl.), S63-68 (2005).
48. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085), 808-812 (2006).
49. Keijzer C, Slutter B, Van Der Zee R, Jiskoot W, Van Eden W, Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE 6(11), e26684 (2011).
50. Krishnamachari Y, Salem AK. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv. Drug Deliv. Rev. 61(3), 205-217 (2009).
51. Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J. Immunother. 30(5), 469-478 (2007).
52. Foged C, Hansen J, Agger EM. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur. J. Pharm. Sci. 45(4), 482-491 (2012).
53. Colaco CA, Bailey CR, Walker KB, Keeble J. Heat shock proteins: stimulators of innate and acquired immunity. Biomed. Res. Int. 2013, 461230 (2013).
54. Beaudette TT, Bachelder EM, Cohen JA et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol. Pharm. 6(4), 1160-1169 (2009).
55. Greenberg NM, Demayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA 92(8), 3439-3443 (1995).
56. Mueller M, Reichardt W, Koerner J, Groettrup M. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J. Control Release 162(1), 159-166 (2012).
57. Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin. Proc. 77(4), 339-349 (2002).
58. Goforth R, Salem AK, Zhu X et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol. Immunother. 58(4), 517-530 (2009).
59. Steele TA. Chemotherapy-induced immunosuppression and reconstitution of immune function. Leukemia Res. 26(4), 411-414 (2002).
60. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 (2008).
61. Vincent J, Mignot G, Chalmin F et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010).
62. Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201(10), 1591-1602 (2005).
63. Gazzaniga S, Bravo AI, Guglielmotti A et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol. 127(8), 2031-2041 (2007).
64. Geary SM, Lemke CD, Lubaroff DM, Salem AK. The combination of a low-dose chemotherapeutic agent, 5-Fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS ONE 8(6), e67904 (2013).
65. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 71(14), 4809-4820 (2011).
66. Frazier JL, Han JE, Lim M, Olivi A. Immunotherapy combined with chemotherapy in the treatment of tumors. Neurosurg. Clin. North Am. 21(1), 187-194 (2010).
67. He Q, Li J, Yin W et al. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer. Cancer Immunol. Immunother. 60(5), 715-730 (2011).